After wrapping up a $200 million renovation at a former Boehringer Ingelheim plant near Cleveland, Ohio, several years back, Danish specialty drugmaker Xellia Pharmaceuticals is paring back its ...

Xellia is a leading developer and manufacturer of anti-infective therapies for multi-drug resistant infections. With this acquisition Novo expands its long-term investment portfolio with a further ...

Civica Rx and Xellia Pharmaceuticals have partnered to manufacture and distribute generic versions of drugs that are in high demand by hospitals but are often in short supply or costly. The companies' ...

COPENHAGEN, Denmark & BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, has appointed Peter Baker as ...

OSLO & COPENHAGEN–(BUSINESS WIRE)–Xellia Pharmaceuticals (“Xellia”), a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, ...

COPENHAGEN, Denmark & BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its ...

Xellia’s US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with Eton Agreement Significantly Expands Biorphen Commercial Footprint and Provides Access to ...

A national pharmaceutical company is planning to lay off more than 200 employees at its Bedford location as it divests the facility along with other business assets. Xellia Pharmaceuticals USA LLC ...

Xellia Pharmaceuticals completed the expansion of its laboratory services building at its Budapest manufacturing site. Xellia Pharmaceuticals, which focuses on providing anti-infective APIs and ...

Xellia Pharmaceuticals (“Xellia”), a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced today that Novo A/S (“Novo”), ...

Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals and purchased all shares of the group for approximately US$ 700 million. Novo A/S, the holding company of ...